Ann: Acrux confirms patent challenge, page-4

Refer to the footnotes in the announcement. This has been well communicated by Acrux for quite a while now, and is pretty central to the current strategy (as it is for anyone in the generic drug business today).

Also, see:
https://en.wikipedia.org/wiki/Drug_Price_Competition_and_Patent_Term_Restoration_Act

"Because the Act also makes clear that filing an ANDA with a paragraph IV certification is an act of patent infringement, the law actually promotes litigation between private parties; the innovator is prompted to commence patent enforcement litigation against the generic infringer, and the generic company is incentivized to file a countersuit to have the patents listed in the Orange Book declared invalid."